Teeple A, Muser E. Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis. J of Skin [Internet]. 2018Dec.17 [cited 2025Jan.10];2:S80. Available from: https://skin.dermsquared.com/skin/article/view/477